PQRS Measure Specifications Table of Contents
The table below includes the list of 2011 PQRS measures that may be reportable by infectious diseases physicians. Click on the individual measures for their specifications.
Some measures have an age, gender, or frequency limitation, such as for
patients with a chronic illness for whom a particular process of care
is provided only periodically.
The measure developer information and applicable reporting options also are included in the table for ease of reference. Individual
infectious diseases specialists' ability to report these measures
depends on their service mix and patient population. Please click here for a complete list of 2011 PQRS measures.
Community-Acquired Pneumonia
Hepatitis C (HCV)
HIV/AIDS
Medication Management
Preventive Care Screening
Wound Care Prevention
56
|
Community-Acquired Pneumonia (CAP): Vital Signs
|
AMA-PCPI/NCQA
|
C, MG, R, GPRO II
|
57
|
Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation
|
AMA-PCPI/NCQA
|
C, MG, R, GPRO II
|
58
|
Community-Acquired Pneumonia (CAP): Assessment of Mental Status
|
AMA-PCPI/NCQA
|
C, MG, R, GPRO II
|
59
|
Community-Acquired Pneumonia (CAP): Empiric Antibiotic
|
AMA-PCPI/NCQA
|
C, MG, R, GPRO II
|
124
|
Health Information Technology (HIT): Adoption/Use of Health Information Technology (Electronic Health Records)
|
CMS/QIP
|
C, R, EHR, GPRO II
|
83
|
Hepatitis C (HCV): Testing for Chronic HCV – Confirmation of HCV Viremia
|
AMA-PCPI
|
R, GPRO II
|
84
|
Hepatitis C (HCV): Ribonucleic Acid (RNA) Testing Before Initiating Treatment
|
AMA-PCPI
|
C, MG, R, GPRO II
|
85
|
Hepatitis C (HCV): Genotype Testing Prior to Treatment
|
AMA-PCPI
|
C, MG, R, GPRO II
|
86
|
Hepatitis C (HCV): Antiviral Treatment Prescribed
|
AMA-PCPI
|
C, MG, R, GPRO II
|
87
|
Hepatitis C (HCV): Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
|
AMA-PCPI
|
C, MG, R, GPRO II
|
89
|
Hepatitis C (HCV): Counseling Regarding Risk of Alcohol Consumption
|
AMA-PCPI
|
C, MG, R, GPRO II
|
90
|
Hepatitis C (HCV): Counseling Regarding Use of Contraception Prior to Antiviral Therapy
|
AMA-PCPI
|
C, MG, R, GPRO II
|
183
|
Hepatitis C (HCV): Hepatitis A Vaccination in Patients with HCV
|
AMA-PCPI
|
C, MG, R, GPRO II
|
184
|
Hepatitis C (HCV): Hepatitis B Vaccination in Patients with HCV
|
AMA-PCPI
|
C, MG, R, GPRO II
|
159
|
HIV/AIDS: CD4+ Cell Count or CD4+ Percentage
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
160
|
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
161
|
HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
162
|
HIV/AIDS: HIV Ribonucleic Acid (RNA) Control After Six Months of Potent Antiretroviral Therapy
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
205
|
HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
206
|
HIV/AIDS: Screening for High Risk Sexual Behaviors
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
207
|
HIV/AIDS: Screening for Injection Drug Use
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
208
|
HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis
|
AMA-PCPI/NCQA
|
MG, R, GPRO II
|
126
|
Wound Care Prevention (Diabetes Mellitus): Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation
|
APMA
|
C, R, GPRO II
|
127
|
Wound Care Prevention (Diabetes Mellitus): Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
|
APMA
|
C, R, GPRO II
|
163
|
Wound Care Prevention (Diabetes Mellitus): Foot Exam
|
NCQA
|
C, R, GPRO II
|
186
|
Wound Care Treatment: Use of Compression System in Patients with Venous Ulcers
|
AMA-PCPI/NCQA
|
C, R, GPRO II
|